CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cellectis S.A.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026
$0.93−0.11 (-11.01%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Cellectis statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Cellectis | Industry median |
|---|---|---|
| Market Cap | $92.86M | $164.85M |
| Enterprise Value | $31.33M | $87.06M |
| PS Ratio | 1.27 | 3.60 |
| PB Ratio | 1.22 | 2.03 |
| P/TBV Ratio | 1.23 | 2.31 |
Enterprise value
| Measure | Cellectis | Industry median |
|---|---|---|
| EV / Sales | 0.43 | 2.43 |
Income (trailing twelve months)
| Measure | Cellectis | Industry median |
|---|---|---|
| Revenue | $72.95M | $57.94M |
| Gross Profit | $72.95M | $90.47M |
| Operating Income | -$33.08M | -$21.44M |
| Pretax Income | -$68.02M | -$14.45M |
| Net Income | -$67.59M | -$22.46M |
| EBITDA | -$13.01M | -$16.91M |
| EPS (Diluted) | -$0.67 | -$0.83 |
Margins
| Measure | Cellectis | Industry median |
|---|---|---|
| Gross Margin | 100.0% | 52.3% |
| Operating Margin | -45.3% | -44.5% |
| Pretax Margin | -93.2% | -13.0% |
| Profit Margin | -92.7% | -39.2% |
| EBITDA Margin | -17.8% | -31.3% |
| FCF Margin | -57.2% | -8.85% |
Returns
| Measure | Cellectis | Industry median |
|---|---|---|
| Return on Equity (ROE) | -65.3% | -53.1% |
| Return on Assets (ROA) | -19.1% | -41.0% |
| Return on Invested Capital (ROIC) | -2430.7% | -32.0% |
| Return on Capital Employed (ROCE) | -18.5% | -37.8% |
Growth
| Measure | Cellectis | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 75.8% | 6.01% |
| FCF Growth (YoY) | -304.7% | 2.34% |
| Revenue Growth (3Y CAGR) | 56.1% | 2.25% |
| Revenue Growth (5Y CAGR) | 7.40% | 6.42% |
Balance sheet
| Measure | Cellectis | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $61.53M | $62.42M |
| Net Cash (Debt) | $61.53M | $15.68M |
| Net Cash Per Share | $0.61 | $0.66 |
| Equity (Book Value) | $75.90M | $48.79M |
| Book Value Per Share | $0.76 | $1.36 |
| Tangible Book Value | $75.37M | $23.06M |
Financial position
| Measure | Cellectis | Industry median |
|---|---|---|
| Quick Ratio | 0.52 | 2.39 |
| Interest Coverage | -0.65 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Cellectis | Industry median |
|---|---|---|
| Operating Cash Flow | -$39.40M | -$12.35M |
| Capital Expenditures | -$2.36M | -$1.06M |
| Free Cash Flow | -$41.76M | -$20.28M |
| FCF Per Share | -$0.42 | -$0.42 |
Efficiency
| Measure | Cellectis | Industry median |
|---|---|---|
| Asset Turnover | 0.21 | 0.38 |
| Revenue Per Employee | $318.56K | $398.96K |
| Profits Per Employee | -$295.17K | -$703.34K |
| Employee Count | 229 | 74 |
Dividends and yields
| Measure | Cellectis | Industry median |
|---|---|---|
| Earnings Yield | -72.8% | -22.7% |
| FCF Yield | -45.0% | -9.07% |
Shares
| Measure | Cellectis | Industry median |
|---|---|---|
| Shares Outstanding | 100,339,000 | 58,179,650 |
| Shares Change (YoY) | 10.7% | 11.1% |
| Float | 45,740,000 | 49,173,100 |
| Shares Held by Insiders | 54.4% | 11.6% |
| Shares Held by Institutions | 9.45% | 59.4% |
Taxes
| Measure | Cellectis | Industry median |
|---|---|---|
| Income Tax | -$423.00K | $91.50K |
Scores
| Measure | Cellectis | Industry median |
|---|---|---|
| Altman Z-Score | 0.11 | -0.24 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Cellectis's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.